This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSCI COSCIENS Biopharma (CSCI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisEarningsHeadlinesTrendsBuy This Stock About COSCIENS Biopharma Stock (NASDAQ:CSCI) Get COSCIENS Biopharma alerts:Sign Up Key Stats Today's Range$2.72▼$2.7250-Day Range$2.61▼$3.9552-Week Range$2.50▼$4.40VolumeN/AAverage Volume7,571 shsMarket Capitalization$8.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada. Read More Receive CSCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COSCIENS Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSCI Stock News HeadlinesCOSCIENS Biopharma Sets July 3 Effective Date for Share Capital Overhaul and U.S. Reporting ExitJune 23, 2026 | tipranks.comCOSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | financialpost.comFTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 30 at 1:00 AM | Porter & Company (Ad)COSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | markets.businessinsider.comCOSCIENS Biopharma Inc. Announces Details of Share Capital AmendmentJune 22, 2026 | globenewswire.comCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18, 2026 | financialpost.comFCOSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEOJune 18, 2026 | globenewswire.comCSCI Leverages Technology, Workforce Expansion, and Operational Discipline to Drive Continued Growth Across FloridaJune 11, 2026 | businesswire.comSee More Headlines CSCI Stock Analysis - Frequently Asked Questions How were COSCIENS Biopharma's earnings last quarter? COSCIENS Biopharma Inc. (NASDAQ:CSCI) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.85) earnings per share (EPS) for the quarter. The business had revenue of $2.75 million for the quarter. COSCIENS Biopharma had a negative trailing twelve-month return on equity of 149.49% and a negative net margin of 199.55%. What other stocks do shareholders of COSCIENS Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that COSCIENS Biopharma investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), Baidu (BIDU). Company Calendar Last Earnings8/14/2025Today6/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CSCI CIK1113423 Webwww.cosciensbio.com Phone49-6942-6020Fax418-948-9191Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.31 million Net Margins-199.55% Pretax Margin-189.27% Return on Equity-149.49% Return on Assets-54.80% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.65 Sales & Book Value Annual Sales$9.44 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.78Miscellaneous Outstanding Shares3,176,000Free Float3,173,000Market Cap$8.64 million OptionableN/A Beta0.91 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CSCI) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe energy story near the Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
